NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/29/2025
Back to search
Official data from USPTO
SYNAPSE MED
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
46
Latest update
07/29/2025
Trademark type
Combined
Nice classes
9, 42, 44
Filing date
10/08/2021
Registration date
07/29/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/29/2025
Last transaction
07/29/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
First use anywhere
2020-06-00
First use in commerce
2020-07-00
Drawing code
5
Owner type
99
Owner location
33000, FR
Examiner
LE, KIEU-NHI NGOC
Law office
O20
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the wording "SYNAPSE" in blue with the wording "MED" in blue superscripted to the right of the "E" in "SYNAPSE".
Holders and representatives
Holders
S. M. (pessoa física)
Representatives
Todd A. Denys Mandelbaum Barrett PC
Technical classification
Nice Classes
Class 9Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 9
Downloadable computer software using artificial intelligence for medical prescription assistancesoftware for word processing and establishing standardized directories; Downloadable computer software using artificial intelligence to avoid medical risks and contraindications and for drug interaction preventionsoftware for word processing and establishing standardized directories; Downloadable computer software using artificial intelligence for medical prescriptions analysissoftware for word processing and establishing standardized directories; none of the above products are for use or provided in the field of medical informatics management and image recognitionAI platforms in the medical field
Class 42
Research in the field of artificial intelligence for computer software design for medical prescription assistancefor the prevention of medicinal riskscontraindications and drug interactions; Research in the field of artificial intelligence for computer software design for prescription analysis; Software design and development for medical prescription assistancefor the prevention of medicinal riskscontraindications and drug interactions; Software design and development for prescription analysis; Software as a service (SAAS) services featuring software using artificial intelligence for word processing and establishing standardized directories in the fields of medical prescription assistancefor the prevention of medicinal riskscontraindications and drug interactions; Software as a service (SAAS) services featuring software using artificial intelligence for word processing and establishing standardized directories for prescription analysis; none of the above services are for use or provided in the field of medical informatics management and image recognitionAI platforms in the medical field; Software as a service (SAAS) services featuring software modules for providing prescription assistance through telemedicine platforms
Class 44
Telemedicine services; Prescription assistance modules in the nature of providing information in the field of medical prescriptions via telemedicine platforms; Providing advice relating to medical services provided via telecommunications technology; providing information in the field of telemedicine; providing information in the field of medical prescription; providing information in the field of medical prescription analysis; none of the above services are for use or provided in the field of medical informatics management and image recognitionAI platforms in the medical field
Publications
History of USPTO decisions and trademark events.
46 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
07/29/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
07/16/2025
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
07/16/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
07/16/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
07/16/2025
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
07/16/2025
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
07/07/2025
SUPC
STATEMENT OF USE PROCESSING COMPLETE
06/07/2025
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
06/03/2025
IUAF
USE AMENDMENT FILED
03/10/2025
EISU
TEAS STATEMENT OF USE RECEIVED
03/10/2025
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
09/10/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/16/2024
PUBO
PUBLISHED FOR OPPOSITION
07/16/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/26/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/11/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
06/07/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
06/07/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
06/07/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
06/07/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/06/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/06/2024
ALIE
ASSIGNED TO LIE
05/06/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/17/2024
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
04/17/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/17/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/17/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/17/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/17/2024
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
12/14/2023
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
09/14/2023
GNSI
INQUIRY TO SUSPENSION E-MAILED
09/14/2023
CNSI
SUSPENSION INQUIRY WRITTEN
09/14/2023
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
02/16/2023
GNSL
LETTER OF SUSPENSION E-MAILED
02/16/2023
CNSL
SUSPENSION LETTER WRITTEN
02/16/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/17/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/16/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/16/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/14/2022
GNRT
NON-FINAL ACTION E-MAILED
07/14/2022
CNRT
NON-FINAL ACTION WRITTEN
07/14/2022
DOCK
ASSIGNED TO EXAMINER
07/13/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/01/2021
NWAP
NEW APPLICATION ENTERED
10/12/2021
Continuous trademark protection
Get notified about every new filing that threatens SYNAPSE MED or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.